SABS Company Profile and Key Details

SABS has shown sold momentum, gaining 7.22% over the past week and 59.76% over the past quarter, though year-to-date performance is up 7.22%. Short-term trend indicators are bearishly aligned (SMA20 1.94%, SMA50 3.99%, SMA200 45.08%). The stock’s 14-day RSI is 55.51 (neutral), while the ATR of 0.28 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -37.42% below its high and over 313.0% above its low. Average 10-day trading volume of 233.12 thousand shares is below the 3-month average of 647.73 thousand, indicating normal recent market interest.

SAB Biotherapeutics, Inc. has 90.99 million shares outstanding. The public float is 59.84 million shares, elevated short interest at 5.78% of float. This equals 4.66 million shares. The short ratio is 9.36 days. Institutional investors hold 75.96% of the float. Insiders own 0.71%. Sullivan Eddie Joe holds 5.23 million shares, HAMILTON CHRISTINE E has 4.99 million shares and Big Cypress Holdings LLC has 3.05 million shares.

SAB Biotherapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.07. This means the shares are trading above this model’s fair value.

The stock is currently mid-range between its 52-week high and low $1.85 and $5.15. With a market capitalization of about $338.47 million, SAB Biotherapeutics, Inc. is classified as a small-cap and shows lower-than-market volatility (beta ~0.53). Key stats such as the average daily volume over the past year has been around 661.84 thousand shares, volume is running light vs its 52-week average. Headquartered in Miami Beach, FL, SAB Biotherapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Samuel J. Reich, the company employs approximately 86 people and listed since February 09, 2021. SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States.

Wall Street analysts project EPS growth of 49.24% annually over the next five years. The latest quarter delivered EPS of -$0.28. The next quarter is forecast at -$0.21. Next year's EPS is expected at $36.69. Analyst sentiment is bullish. Analyst rating data shows there are 13 Strong Buy ratings, 13 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $16.00 to $7.00. The high target offers 330.11% upside. The low target suggests 88.17% downside. The mean target is $9.77. This offers 162.63% upside. SAB Biotherapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended August 06, 2026, missed forecasts by -1.06%. The prior quarter beat by 75.0%. Over the last six quarters, Apple has recorded several small beats. These include -44.0% in May 09, 2025.

SAB Biotherapeutics, Inc. trades at a P/E ratio of 1.04, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 1.38 suggesting the stock is closer to book value. The P/FCF stands at -4.65, also below market averages.

Our AI price prediction model suggests that SAB Biotherapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 1.08%, with price expected at $3.76 by September 17, 2026, within a range of $3.65 to $3.87 3-Month Outlook: Projected rise of 59.68%, reaching $5.94 by December 02, 2026, with a range of $5.71 to $6.20. 1-Year Outlook: Projected gain of 306.99%, with price at $15.14 by September 03, 2027, within a range of $12.24 to $19.75.

SAB Biotherapeutics, Inc. (NASDAQ:SABS) shares are flat 7.22% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows SAB Biotherapeutics, Inc. trading at a premium to the broader market with a P/E of 1.04. Analyst sentiment is bullish, with the majority of ratings in Overweight territory and a mean price target of $9.24, suggesting 148.39% upside. Our AI forecast model points to short-term strength (1.08% over two weeks), a medium-term rise (59.68% over three months), and a longer-term gain (306.99% over one year), with expected trading ranges indicating moderate volatility.